본문 바로가기
KERD
논문KCI 등재

항정신병약물로 초래되는 체중 증가와 세로토닌 수송체 유전자 다형성 간의 연관성

Association of Serotonin Transporter Gene Polymorphism(5-HTTLPR) with Antipsychotics-Induced Weight Gain

김영훈|정치영|박세현|하태민|공보금|최석주
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2004.12|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제10권 제2호|pp. 150-161

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Weight gainAntipsychotics항정신병약물·체중 증가·세로토닌·유전적 다형성.Serotonin5-HTTLPR (5-HT transporter polymorphic region)
주제분류정신과학

초록

목 적： 정신분열병 환자의 치료에서 항정신병약물 복용으로 불가피하게 유발되는 체중 증가에 대한 예측 및 위험인자로서 세로토닌수송체 유전적 다형성인 5- HTTPLR이 활용될 수 있는지를 평가하고자 하였다. 방 법： 대상자는 DSM-IV 진단 기준에 부합하고, 최소 12주 이상 대상 항정신병약물 중 한 가지를 단독 복용한 161명의 정신분열병 환자들이었다. 조사 내용은 환자의 성, 연령, 체질량지수, 체중, 약물 종류와 사용기간 등과, 5-HTLPR(5-HT transporter-linked polymor-phic region)의 4 bp insertion/deletion 다형성 분포와 대립 유전자빈도였다. 자료 분석에는 SAS(Ver. 8.1) program을 적용하였다.

Abstract

Objectives : Using an independent Korean sample, we investigated the association of sex, age, baseline BMI(body mass index) and 44 bp insertion/deletion polymorphism in 5-HTTLPR (5-HT transporter-linked polymorphic region) with antipsychotics-induced weight gain in patients with schizophrenia. Methods : 161 subjects were fulfilling with the DSM-IV crieteria for schizophrenia. All patients had taken antipsychotics for at least 12 weeks. We reviewed weight changes. We examined the genotype distribution and allele frequency of the serotonin transporter gene 5-HTTLPR in all subjects, using polymerase chain reaction (PCR) of genomic DNA with primers flanking the promotor regions of the 5-HTT gene. Results : There was a significant increase of body weight in those patients whose physical status were female, under 30 years old and under 25 of BMI. Subjects taken atypical antipsychotics were a significant increase of body weight. There was no significant difference in the genotype distribution and allele frequency of 5-HTTLPR between antipsychotics-induced weight gain. Conclusion : There was significant weight gain in female, under 30 years old, under 25 of BMI and taking atypical antipsychotic-medication. These results showed that the genetic polymorphism in 5-HTTLPR is not significantly associated with antipsychotics-induced weight gain in Korean schizophrenic patients.

참고문헌 (57)

  1. "Weight gain associated with antipsychotic drugs", 60, pp.20~24 (1996)
  2. "Weight gain associated with neuroleptic medication", 21, pp.463~472 (1995)
  3. "비전형적 항정신병 약물에서의 체중 증가", 11, pp.335~342 (2001)
  4. "Too many chronic men-taly disabled patients are too fat", 72, pp.254~8 (1985)
  5. "항정신병약물로 초래된 비만의 기전과 치료", 7, pp.278~287 (2001)
  6. "비정형 항정신병 약물과 관련된 체중 증가에 대한 고찰", 3, pp.3~16 (2001)
  7. "Risperidone,a novel antipsychotics and weight change", 13, pp.92~ (1993)
  8. "Extrapyramidal side effects and tolerabi-lity of risperidone", 55, pp.29~35 (1994)
  9. "Double-blind comparison of olna-zapine versus risperidone in the treatment of schizoph-renia and other psychotic disorders", 17, pp.407~18 (1997)
  10. "Novel antipsychotics:Comparison of weight gain liabilities", 60, pp.358~363 (1999)
  11. "Weight gain among schizophrenic patients treated with cloza-pine", 149, pp.689~90 (1992)
  12. "Weight gain:Side effect of atypical neuroleptics", 19, pp.316~332 (1999)
  13. "Bodyweight gain associated with atypical antipsychotics", 15, pp.537~551 (2001)
  14. "Adverse effects of atypical antipsychotics", 62, pp.7~10 (2001)
  15. "Weight gain aso-－ 160 － ciated with clozapine", 147, pp.503~4 (1990)
  16. "Olanzapine:weight gain and therapeutic efficacy", 9, pp.273~5 (1991)
  17. "Olnazapine versus halo-peridol:Acute phase results of the international double blind olanzapine trial", 7, pp.125~137 (1997)
  18. "Olanzapine in-creases weight and serum triglyceride levels", 174, pp.15~22 (1999)
  19. "Atypical antipsychotics and wei-ght gain-a systemic review", 101, pp.416~432 (2000)
  20. "Serotoninergic mechanism in psychiatric disorder:new research tools,new ideas", 8, pp.53~6 (1993)
  21. "The serotonin hypothesis of major depression", pp.933~944 (1995), Raven Pres
  22. "Serotonin, schizophrenia and antipsychotic drug action", pp.187~202 (1995), Schizophr Res
  23. "Cloning & expression of a functional serotonin transporter from rat brain", 354, pp.66~70 (1991)
  24. "Antidepressants and cocaine-sensitive human serotonin transporter:molecular cloning,expresion and chromosomal localization", 90, pp.2542~6 (1993)
  25. "Alelic variation of human serotonin trans-porter gene expression", 66, pp.2621~2641 (1996)
  26. "Cocaine,ethanol,and genotype effects on human midbrain serotonin trans-porter binding sites and mRNA levels", 155, pp.207~213 (1998)
  27. "The human serotonin transporter gene linked polymorphism(5-HTTLPR)show ten novel alelic variants", 5, pp.32~38 (2000)
  28. "sero-tonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa", 5, pp.233~241 (2000)
  29. "Analysis of the serotonin transporter gene linked polymorphsim(5-HTTLPR) in anorexia nervosa.", 96, pp.53~55 (2000)
  30. "Association of a functional 5-HT transpoter gene polymorphism with anorexia nervosa and fod intake", 6, pp.9~10 (2001)
  31. "5-HT2A receptor gene polymorphsims,ano-rexia nervosa,and obesity", 350, pp.1324~5 (1997)
  32. "Obesity in Bahraini adults", 116, pp.30~32 (1996)
  33. "Adverse effects of atypical anti-psychotics", 62, pp.7~10 (2001)
  34. "Bodyweight gain asociated with atypical antipsychotics", 15, pp.537~551 (2001)
  35. "The efect of long-term antipsychotic treat-ment on the body weight of patients suffering from chronic schizophrenia:Clozapine versus classical anti-psychotic agents", 14, pp.229~232 (1999)
  36. "The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentra-tions", 26, pp.41~54 (1997)
  37. "Olanzapine versus halo-peridol in the treatment of schizophrenia and schizoaf-fective and schizophreniform disorders:results of an international collaborative trial", 154, pp.457~465
  38. "Risperidone versus clozapine in treat-ment-resistant chronic schizophrenia:A randomized double-blind study", 155, pp.499~504 (1998)
  39. "Clozapine and weight gain", 5 suppl b, pp.157~60 (1994)
  40. "Weight gain:side efect of atypical neuroleptics", 19, pp.316~321 (1999)
  41. "Diet and gender moderate clozapine", 10, pp.367~371 (1995)
  42. "Safety of olanzapine", 58, pp.13~17 (1997)
  43. "Long-term Olanzapine treatment:weight change and weight-related health factors in schi-zophrenia", 62, pp.92~100 (2001)
  44. "Receptor pharmacology of neuroleptics: Relation to clinical effects", 60, pp.5~14 (1999)
  45. "The 5-HT1B receptor", 600, pp.132~47 (1990)
  46. "5-HT2C re-ceptor modulation and the treatment of obesity", 1, pp.207~214 (1999)
  47. "BW723C86, a 5-HT2B receptor agonist, causes hyperphagia and redu-ced grooming in rats.", 36, pp.233~239 (1997)
  48. "Effects of peri-pheral 5-HT2 and 5-HT3 receptor agonists on food intake in food-deprived and 2-deoxy-D-glucose-treated rats", 316, pp.15~21 (1996)
  49. "Association between a polymorphism of the 5-HT 2C receptor and weight los in tenage girls", 26, pp.789~793
  50. "Association of anti-psychotic drug induced weight gain with a 5-HT2C re-ceptor gene polymorphism", 359, pp.2086~2087 (2002)
  51. "정신분열병 음성 증상과 5-HTTLPR간의 연관성", 14, pp.138~144 (2003)
  52. "Alelic variation of human serotonin trans-porter gene expression", 66, pp.2621~2624 (1996)
  53. "A novel functional polymorphism wi-thin the promoter of the serotonin transporter gene:possible role in susceptibility to affective disorders", 1, pp.453~460 (1996)
  54. "Association sutidies of bipolar di-sorder at the human serotonin transporter gene", 4, pp.280~283 (1999)
  55. "Tardive dyskinesia is not associated with the serotonin gene polymorphism(5-HTTLPR)in Chinese", 96, pp.712~715 (2000)
  56. "Serotonin transporter gene(5-HTTLPR)and major psychoses", 7, pp.95~99 (2002)
  57. "Susceptibility for schizophrenia is not influenced by a functional insertion", deletion variant in the promoter of the serotonin transporter gene, 1998, pp.248, 82~86

관련 논문AI추천

조현병 환자에서 아미설프라이드에 의한 체중증가와 도파민 D2 수용체 유전자다형성의(rs1800497) 연관성김지현, 서민재, 우정민, 이종훈, 최성민, 최태영대한생물치료정신의학회 · 생물치료정신의학2014 · 제20권 제3호Association between Clozapine-induced Weight Gain and Serotonin 5-HT2C Receptor Gene Polymorphism in Korean Schizophrenic PatientsCheol Min Kim, Dong Hun Shin, Hak Jung Kim, Young In Chung대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2004 · 제2권 제1호정신분열병 환자에서 항정신병 약물로 발생한 체중 증가의 유전적 원인： 연합 연구를 중심으로박영민, 이헌정, 정영조대한생물치료정신의학회 · 생물치료정신의학2007 · 제13권 제2호한국인 정신분열병 환자에서 비정형 항정신병 약물의 치료반응과 체중증가의 관련성에 대한 연구이민수, 이재병, 이화영, 함병주대한생물정신의학회 · 생물정신의학2011 · 제18권 제4호도파민/세로토닌 길항성 비정형 항정신병약물로 치료 중인 정신분열병 환자에서 체중 증가의 관련 요인김신겸, 박동연, 이동수, 장원석, 최경숙, 한우상, 홍경수대한신경정신의학회 · 신경정신의학2004 · 제43권 제3호항정신병약물을 처음으로 사용하는 초발 정신증 환자에서 나타나는 체중 및 대사성 지표의 변화 : 후향적 연구강제욱, 공보금, 김민걸, 김성진, 김우진, 김정은, 김현정, 문정준, 박민경, 심주철, 정도운대한생물치료정신의학회 · 생물치료정신의학2011 · 제17권 제2호

이 간행물의 다른 논문 (7건)

두통의 임상적 평가-일이차 두통의 감별진단도진국pp. 137-142정신분열병의 발병연령에 따른 할로페리돌 투여 전후의 혈장 Homovanillic Acid, 3-Methoxy-4-Hydroxyphenylglycol의 농도 변화한규희, 김봉조, 홍정원pp. 143-149βTC-6 세포에서 Fluoxetine과 Mirtazapine이 인슐린 분비에 미치는 영향박기창, 이건일, 전성균, 장형민, 공인덕pp. 162-171만성 정신분열병 및 분열정동장애 환자에서 Risperidone, Olazapine 그리고 Quetiapine의 치료 효과와 안정성에 대한 전향적 비교 연구김정기, 주명진, 조지현, 강승훈, 이수진pp. 172-183한국에서 11년간 Clozapine 투여에 의한 무과립구증과 호중구감소증이양현, 조만제, 오정태, 강병조pp. 184-191
원문 보기